INmune Bio Q2 2024 GAAP EPS $(0.50) Beats $(0.63) Estimate
Portfolio Pulse from Benzinga Newsdesk
INmune Bio (NASDAQ:INMB) reported a Q2 2024 GAAP EPS of $(0.50), beating the analyst consensus estimate of $(0.63) by 20.63%. This represents a 38.89% increase in losses compared to the same period last year.
August 01, 2024 | 8:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio reported a Q2 2024 GAAP EPS of $(0.50), beating the analyst consensus estimate of $(0.63) by 20.63%. Despite the beat, the losses increased by 38.89% compared to the same period last year.
The better-than-expected EPS is likely to have a positive short-term impact on INMB's stock price, as it shows the company is performing better than analysts anticipated. However, the increase in losses compared to last year may temper some of the optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100